The clinical management of adult growth hormone deficiency (GHD) comprises caring for patients who are transitioning from pediatric to adult services, as well as patients with adult-onset (AO) GHD. There are unique challenges and opportunities in both scenarios, including who and when to test, which diagnostic tests to use, consideration of current and emerging treatment strategies, and improving patient adherence to therapies. The “art of medicine” and shared decision-making play important roles in GHD – as both medical and psychological factors need to be addressed to optimize outcomes.
In this OnDemand CMEO symposium, three experts in GHD follow the patient journeys of a young adult transitioning from pediatric care and a 50-year-old patient with AO-GHD. Clinical application of guidelines, a review of key study results, and the role of long-acting growth hormone preparations will be discussed.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Novo Nordisk, Inc.
Physicians, PAs, nurse practitioners, nurses, and pharmacists specializing in endocrinology.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Yuen reports the following financial relationships: Advisory Board: Amryt Pharma; Ascendis Pharma Group; Corcept; Crinetics; Ipsen Pharma; Novo Nordisk; Rani Therapeutics; Recordati; and Strongbridge Biopharma. Research Support: Grants paid to Barrow Neurological Institute: Amryt Pharma; Ascendis Pharma Group; Corcept; and Novartis
Dr. Molitch reports the following financial relationships: Advisory Board: Strongbridge Biopharma. Consultant: Amryt Pharma and Corcept
Dr. Silverstein reports the following financial relationships: Advisory Board: Chiasma, Inc.; Recordati S.p.A.; and Strongbridge Biopharma plc
Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer)
Warren Beckman (planning committee)
Kathleen Blake, PhD (planning committee)
Thomas Mitchell (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sharon Tordoff (planning committee)
Disclosures were obtained from the CME Outfitters, LLC, staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-082-H01-P.
Call us at 877.CME.PROS (877.263.7767).